Cyclo Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CYTH and buy or sell other stocks, ETFs, and their options commission-free!About CYTH
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease.
CEOScott Fine
CEOScott Fine
Employees—
Employees—
HeadquartersGainesville, Florida
HeadquartersGainesville, Florida
Founded1990
Founded1990
Employees—
Employees—
CYTH Key Statistics
Market cap23.72M
Market cap23.72M
Price-Earnings ratio-0.81
Price-Earnings ratio-0.81
Dividend yield—
Dividend yield—
Average volume22.85K
Average volume22.85K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$1.62
52 Week high$1.62
52 Week low$0.55
52 Week low$0.55
Stock Snapshot
With a market cap of 23.72M, Cyclo Therapeutics(CYTH) trades at $0.72. The stock has a price-to-earnings ratio of -0.81.
On 2025-12-25, Cyclo Therapeutics(CYTH) stock opened at —, reached a high of —, and a low of —.
The Cyclo Therapeutics(CYTH)'s current trading volume is 0, compared to an average daily volume of 22.85K.
During the past year, Cyclo Therapeutics(CYTH) stock moved between $0.55 at its lowest and $1.62 at its peak.
During the past year, Cyclo Therapeutics(CYTH) stock moved between $0.55 at its lowest and $1.62 at its peak.
People also own
Based on the portfolios of people who own CYTH. This list is generated using Robinhood data, and it’s not a recommendation.